Last reviewed · How we verify
NCT05175521
Inhaled IAV vs Inhaled Eucalyptus for the Treatment of Nausea With Acute Migraine
NA trial testing Eucalyptus Oil Scent in Migraine in 21 participants. Completed in 1 April 2026.
31 December 2025
Quick facts
| Lead sponsor | HonorHealth Research Institute |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | supportive care |
| Enrollment | 21 |
| Start date | 11 November 2021 |
| Primary completion | 31 December 2025 |
| Estimated completion | 1 April 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Eucalyptus Oil Scent
- Isopropyl Alcohol Vapors
Conditions studied
- Migraine — all drugs for Migraine →
Sponsor
HonorHealth Research Institute
Who can join
Adults 18 to 65, any sex, with Migraine. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study is to compare the efficacy and adverse events of inhaled isopropyl alcohol vapor (IAV) versus placebo (inhaled eucalyptus scent (IES) (1:20 dilution in mineral oil) for treating nausea associated with acute migraine attacks.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05175521
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Migraine
Currently open trials in the same condition.
- NCT07419607 — MIGRAFIT: Evaluating a Group Therapy Program Combining Physical Activity, Progressive Muscle Relaxation and Psychoeducat · NA · recruiting
- NCT07487701 — Migraine Prevention With the Remote Electrical Neuromodulation (REN) Wearable: A Real-world Evidence Study · NA · active not recruiting
- NCT07343427 — Impact of GON PRF on Central Sensitization in Migraine Patients · NA · active not recruiting
- NCT07336056 — Nerivio Efficacy Under High-Frequency Use · Phase 4 · active not recruiting
- NCT07385755 — Desvenlafaxine for Preventive Treatment of Frequent Migraines · NA · active not recruiting
Other HonorHealth Research Institute trials
Trials by the same sponsor.
- NCT05229588 — Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations · Phase 2 · completed
- NCT05216120 — Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas · Phase 2 · withdrawn
- NCT05004025 — Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma · Phase 1 · completed
- NCT04611139 — Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers · Phase 1 · withdrawn
- NCT05068752 — Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05175521 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by HonorHealth Research Institute
- Last refreshed: 17 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05175521.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing